NASDAQ: MDWDMediwound Ltd Stock
$17.59+1.18 (+7.19%)
Updated Apr 24, 2024
MDWD Price
$17.59
Fair Value Price
-$5.80
Market Cap
$162.21M
52 Week Low
$7.10
52 Week High
$18.75
P/E
-23.45x
P/B
5.13x
P/S
4.91x
PEG
N/A
Dividend Yield
N/A
Revenue
$18.69M
Earnings
-$6.72M
Gross Margin
19.1%
Operating Margin
-24.83%
Profit Margin
-35.9%
Debt to Equity
1.1
Operating Cash Flow
-$10M
Beta
0.69
Next Earnings
May 28, 2024
Ex-Dividend
N/A
Next Dividend
N/A
MDWD Overview
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how MDWD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MDWD ($17.59) is overvalued by 403.45% relative to our estimate of its Fair Value price of -$5.80 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
MDWD ($17.59) is not significantly undervalued (403.45%) relative to our estimate of its Fair Value price of -$5.80 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
MDWD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more MDWD due diligence checks available for Premium users.
Be the first to know about important MDWD news, forecast changes, insider trades & much more!
MDWD News
Valuation
MDWD fair value
Fair Value of MDWD stock based on Discounted Cash Flow (DCF)
Price
$17.59
Fair Value
-$5.80
Undervalued by
403.45%
MDWD ($17.59) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
MDWD ($17.59) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
MDWD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
MDWD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-23.45x
Industry
15.69x
Market
41.27x
MDWD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.13x
Industry
5.86x
MDWD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MDWD's financial health
Profit margin
Revenue
$5.3M
Net Income
-$1.7M
Profit Margin
-32.7%
MDWD's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
MDWD's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$66.5M
Liabilities
$34.9M
Debt to equity
1.1
MDWD's short-term assets ($49.70M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MDWD's short-term assets ($49.70M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MDWD's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
MDWD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.6M
Investing
$5.0M
Financing
-$204.0k
MDWD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MDWD vs Biotech Stocks
Mediwound Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.